CAMBRIDGE, Massachusetts - Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors -
Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana’s biodegradable polymer platform, Fleximer(R).
Ten of 37 evaluable patients dosed to date demonstrated evidence of stable disease and seven patients had prolonged stable disease for at least 12 weeks. The study has also demonstrated that XMT-1001 can be safely given to patients. Toxicities such as hemorrhagic cystitis and serious diarrhea were not observed in this preliminary assessment. In addition, a favorable pharmacokinetic profile was observed. Full text of the abstract can be viewed online at the ASCO website at www.abstract.asco.org.
“We are encouraged by the favorable safety and pharmacokinetic profile demonstrated by XMT-1001 thus far,” said Julie Olson, Chief Executive Officer of Mersana. “These preliminary results build on our preclinical studies, which showed that XMT-1001 has greater efficacy in human tumor xenograft models than comparable doses of irinotecan, an agent with a similar mechanism of action as camptothecin and that is approved to treat patients with colon cancer. We look forward to advancing XMT-1001 into a Phase 2 trial in a solid tumor indication.”
About the XMT-1001 Preliminary Study
The Phase 1 trial is an open label, dose escalation study of XMT-1001 administered as an IV infusion once every three weeks in patients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics. The maximum tolerated dose is not yet defined and accrual to the study continues.
ASCO Poster Information
“A Phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors.”
By E. Sausville, L. Garbo, G. J. Weiss, S. Anthony, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; TGen Clinical Research Services, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI
Session: Developmental Therapeutics: Cytotoxic Chemotherapy Type: General Poster Session Time: Saturday May 30, 2009, 8:00 AM to 12:00 PM Location: Level 2, West Hall C
About Fleximer(R)
The key component of Mersana’s platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Fleximer(R) technology improves the therapeutic index of existing compounds by uniquely combining biodegradability with “biological stealth” properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized by solubility in water, with stability in common manufacturing procedures.
About Mersana Therapeutics, Inc.
Mersana Therapeutics employs its biodegradable polymer platform (Fleximer(R)) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.
Mersana is headquartered in Cambridge, MA and its investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures. For more information, visit www.mersana.com.
Fleximer(R) and Mersana(R) are registered trademarks of Mersana Therapeutics, Inc.
Source: Mersana Therapeutics, Inc.
Kathryn Morris of KMorrisPR, +1-845-635-9828, kathryn at kmorrispr.com
Related Press Releases
Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve RepairSeptember 21st, 2009 SAN FRANCISCO -
- Results of Histopathology and Mechanical Integrity Analysis of MitraClip(R) Devices Presented at TCT 2009
The mechanical integrity of the MitraClip(R) device for repair of the mitral valve was maintained for up to five years and with complete healing, according to a subset of data from the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data also show complete fibrous encapsulation of the MitraClip device with organized, endocardial tissue growth demonstrating complete healing and incorporation of the implant within the native mitral valve.
MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral RegurgitationSeptember 21st, 2009 SAN FRANCISCO -
- 12-Month Data Presented at TCT 2009 Show Significant Improvement in Left Ventricular Function with no Change in Annular Dimensions
Sustained reduction of mitral regurgitation following mitral valve repair with the MitraClip(R) system in patients with degenerative mitral regurgitation (DMR) or functional mitral regurgitation (FMR) led to heart function improvements, according to 12-month data from a subset of the initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) studies presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data were presented today by Scott Lim, M.D., interventional cardiologist at the University of Virginia Medical Center and one of the EVEREST trial investigators.
MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral RegurgitationSeptember 21st, 2009 SAN FRANCISCO -
- 12-Month Data Also Demonstrate Significant Reduction in Left Ventricular Volumes
Twelve-month data from EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study high-risk registry arm presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco show that high risk patients with functional mitral regurgitation (MR) following valve repair with the MitraClip(R) system showed a reduction in mitral annular dimension, improvement in heart function and a reduction in hospitalization for congestive heart failure. The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center, Los Angeles, CA and the lead enrolling investigator of the EVEREST II trial.
Six Month Clinical Outcomes of Sahajanand Medical Technologies Supralimus - Sirolimus Eluting Stent presented at EuroPCR 09September 18th, 2009 BARCELONA, Spain, May 20, 2009 - Six months Clinical outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry.
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 CongressSeptember 15th, 2009 THOUSAND OAKS, California -
- Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented
Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany. Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the '136' study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the '244' study).
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly PatientsJune 10th, 2009 SEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington.
Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck CancerMay 29th, 2009 MADRID - Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone -
The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC). The endpoint of Time-to-Treatment Failure was defined as a composite of time-to-disease progression, -to-surgery or other cancer-related treatments, -to-drop-out due to an adverse event, and to death from any cause.
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast CancerMay 28th, 2009 COLLEGEVILLE, Pennsylvania - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data gathered from both trials are scheduled to be presented at the 45th Annual Meeting of the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, from May 29 to June 2, 2009.
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research MeetingApril 18th, 2009 CAMBRIDGE, Massachusetts - Data Show Fleximer(R) Extends Exposure to Conjugated Drug -
Mersana, a platform-based cancer therapeutics company, today announced positive results of preclinical studies for its second development candidate, XMT-1107, in two posters at the 2009 Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The studies showed that XMT-1107, a novel anti-angiogenic fumagillin analog conjugated to Mersana's proprietary Fleximer(R), demonstrated superior anti-tumor activity in tumor xenograft models in comparison to other anti-angiogenic agents and extended exposure to the conjugated drug, supporting the potential clinical utility of XMT-1107 as an anti-cancer agent.
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow TransplantationsApril 7th, 2009 AMSTERDAM - ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium
Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr.
Related News
Manipur sees 60 percent polling in second phaseApril 22nd, 2009 IMPHAL - Voting for the second and final phase of parliamentary elections in Manipur -- to the Inner Manipur constituency -- ended Wednesday with no incidents of violence, officials said. 'According to preliminary reports, an estimated 60 percent polling was recorded, although the figure could increase as we are still in the process of compiling data from remote areas,' an election official said.
Contrave - Weight-Loss Drug Trials Meet GoalsJuly 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss
in three late-stage clinical trials according to Associated Press reports.
Vitamin D deficiency may worsen chronic painMarch 21st, 2009 WASHINGTON - Vitamin D deficiency might worsen the condition of people suffering from chronic pain, according to a new study. The research from Mayo Clinic has found a link between inadequate vitamin D levels and the amount of narcotic medication taken by patients who have chronic pain.
Quarterly earnings of major companies tentatively scheduled for the week of 8/10/09August 6th, 2009 Earnings schedule for week of 8/10/09Major companies tentatively scheduled to report quarterly earnings next week:
Monday
ENGLEWOOD, Colo. — Dish Network Corp.
Wills 'to begin advanced helicopter training'April 18th, 2009 LONDON - Prince William has reportedly completed his basic flight training and will move on to a more advanced learning as he trains to become a search and rescue helicopter pilot with the Royal Air Force. The 26-year-old was said to have already learnt risky night and instrument flying, forced landings, and emergency work in Squirrel choppers.
Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.
Juniper Networks reports 1st-quarter loss on lower revenue and one-time chargeApril 23rd, 2009 Juniper preliminary results show 1Q lossSUNNYVALE, Calif. — Network equipment maker Juniper Networks Inc.
Earnings schedule for week of 6/15/09June 11th, 2009 Earnings schedule for week of 6/15/09Major companies tentatively scheduled to report quarterly earnings next week:
Monday
No major announcements. Tuesday
SAN JOSE, Calif.
Stocks trade mixed after weeklong stretch of gains; Advanced Micro, Wells Fargo disappointJuly 22nd, 2009 Stocks zigzag as companies post mixed resultsNEW YORK — Investors are taking a wary view of the latest batch of corporate earnings reports following a weeklong winning streak. Stocks traded mixed early Wednesday following a batch of uneven corporate results.
102-year-old leprosy patient casts vote in HimachalMay 13th, 2009 SHIMLA - Bir Singh, a 102-year-old leprosy patient, exercised his franchise at a special polling booth in Himachal Pradesh in the fifth and final phase of general elections Wednesday. 'Bir Singh was among the 13 voters who exercised franchise this morning at a special polling station set up for the leprosy patients in Solan district,' state chief electoral officer Anil Khachi told IANS.
